Most Read Articles
Elvira Manzano, 15 hours ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 21 hours ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.

Dupilumab improves symptoms, quality of life of patients with chronic nodular prurigo

19 Jun 2020

Use of dupilumab helps reduce itch and improve chronic nodular prurigo (CNPG) skin lesions, a recent study has shown.

“CNPG is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life,” the author said.

This retrospective, multicentre study was conducted to assess the effectiveness and tolerability of dupilumab in treating adult patients with CNPG refractory to both topical and systemic therapies. Participants received dupilumab for at least 16 weeks.

Twenty-seven patients with CNPG achieved clinical improvement in terms of itch, skin lesions, sleeplessness, and quality of life. Of the participants, 24 (88.9 percent) had at least 16-week continuous treatment, and 11 of these patients (45.8 percent) had Investigator Global Assessment (IGA) score 1. Nineteen of 24 patients (79.2 percent) achieved at least a 2-grade reduction in IGA score.

At week 16, numeric rating scale values decreased from 8.9 to 2.7 for itch and from 8.2 to 1.7 for sleeplessness (p<0.001). Furthermore, 10 patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.

The study had several limitations, including a lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.

A recent study also reported the beneficial effects of dupilumab in patients with bullous pemphigoid, resulting in disease clearance or satisfactory response in several patients. [J Am Acad Dermatol 2020;83:46-52]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 15 hours ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 21 hours ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.